BG103114A - Съдържащи флуор 1,4-дизаместени производни на пиперидин - Google Patents

Съдържащи флуор 1,4-дизаместени производни на пиперидин

Info

Publication number
BG103114A
BG103114A BG103114A BG10311499A BG103114A BG 103114 A BG103114 A BG 103114A BG 103114 A BG103114 A BG 103114A BG 10311499 A BG10311499 A BG 10311499A BG 103114 A BG103114 A BG 103114A
Authority
BG
Bulgaria
Prior art keywords
hydrogen atoms
groups
group
arylalkenyl
heteroarylalkyl
Prior art date
Application number
BG103114A
Other languages
English (en)
Inventor
Yoshimi Tsuchiya
Takashi Nomoto
Kazuaki Hayashi
Kumiko Kawakami
Kenji Ohwaki
Masaru Hishikibe
Original Assignee
Banyu Pharmaceutical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharmaceutical Co., Ltd filed Critical Banyu Pharmaceutical Co., Ltd
Publication of BG103114A publication Critical patent/BG103114A/bg

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Съединенията са полезни за лечение или профилактика на заболявания на дихателната, пикочната и храносмилателната система, имат малко странични ефектии са безвредни и ефективни. Те проявяват селективна антагонистична активност спрямо мускаринови М3 рецептори и са активни при орално приложение, иматпродължително действие и фармакокинетика. Съединенията и техните фармацевтично приемливи соли са с обща формула, в която Ar означава арилова или хетероарилова група с 1 до 2 хетероатома, избрани от групата азот, кислород и сяра, като всеки водороденатом от 1 до 3 от пръстенана ариловата или хетероариловата група може да бъде заместен с нисш алкили т.н.; R1 е С3-С6 циклоалкил, всеки от чиито 1 до 4 водородни атоми могат да бъдат заместени с флуорен атом(и); R2 е С5-С15 наситени или ненаситени алифатни въглеводородни групи, всеки от чиито 1 до6 водородни атома може да бъде заместен с флуоренатом(и), групите аралкил, арилалкенил, хетероарилалкил или хетероарилалкенил с 1 до 2 хетероатома, избрани от групата азот, кислород и сяра (в даден случай всеки от водородните атоми от 1 до 3 от пръстена на групите аралкил, арилалкенил, хетероарилалкил или хетероарилалкенилможе да бъде заместен с нисш алкил, трифлуорометил, циано, хидрокси, нитро, нисш алкоксикарбонил, халоген, нисш алкокси, илиамино и т.н.) и Х означава О или NH, при условие,че поне един от R1 и R2 съдържа един или повече флуорни атоми.
BG103114A 1996-08-01 1999-01-25 Съдържащи флуор 1,4-дизаместени производни на пиперидин BG103114A (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP21943696 1996-08-01
JP5397997 1997-02-21
PCT/JP1997/002600 WO1998005641A1 (en) 1996-08-01 1997-07-28 Fluorinated 1,4-disubstituted piperidine derivatives

Publications (1)

Publication Number Publication Date
BG103114A true BG103114A (bg) 1999-11-30

Family

ID=26394715

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103114A BG103114A (bg) 1996-08-01 1999-01-25 Съдържащи флуор 1,4-дизаместени производни на пиперидин

Country Status (29)

Country Link
US (2) US5948792A (bg)
EP (1) EP0930298B1 (bg)
JP (1) JP3063164B2 (bg)
KR (1) KR20000022214A (bg)
CN (1) CN1226888A (bg)
AR (3) AR008272A1 (bg)
AT (1) ATE229941T1 (bg)
AU (1) AU716050B2 (bg)
BG (1) BG103114A (bg)
BR (1) BR9711108A (bg)
CA (1) CA2261680C (bg)
CO (1) CO4960641A1 (bg)
CZ (1) CZ33199A3 (bg)
DE (1) DE69718026T2 (bg)
EE (1) EE9900038A (bg)
ES (1) ES2188961T3 (bg)
HR (1) HRP970426A2 (bg)
HU (1) HUP9902381A3 (bg)
ID (1) ID17259A (bg)
IL (1) IL127685A0 (bg)
IS (1) IS4960A (bg)
NO (1) NO990472L (bg)
NZ (1) NZ333842A (bg)
PE (1) PE92198A1 (bg)
PL (1) PL331431A1 (bg)
SK (1) SK12299A3 (bg)
TR (2) TR199900204T2 (bg)
WO (1) WO1998005641A1 (bg)
YU (1) YU1299A (bg)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180823B1 (en) 1998-11-06 2001-01-30 Sepracor Inc. Stereoselective process for alkyl phenylglycolic acids
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
WO2000061572A1 (en) * 1999-04-08 2000-10-19 Merck & Co., Inc. Diastereoselective preparation of michael adducts
WO2000066579A1 (en) * 1999-04-28 2000-11-09 Banyu Pharmaceutical Co., Ltd. Processes for the preparation of piperidylmethylpyridine derivatives
CO5440228A1 (es) * 1999-08-23 2004-09-30 Lunbeck As H Tratamiento de la incontinencia urinaria
AU783095B2 (en) * 1999-12-07 2005-09-22 Theravance Biopharma R&D Ip, Llc Carbamate derivatives having muscarinic receptor antagonist activity
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
JP4782342B2 (ja) * 1999-12-17 2011-09-28 サノフィ−アベンティス フェノキシプロパノールアミン類、それらの製造方法およびそれらを含む医薬組成物
US6403818B1 (en) 2000-02-28 2002-06-11 Eisai Co., Ltd. Process for producing α-hydroxy-carbonyl compound
US6469172B2 (en) 2000-03-08 2002-10-22 Merck & Co., Inc. Process for the preparation of chemical compounds
US6403584B1 (en) * 2000-06-22 2002-06-11 Merck & Co., Inc. Substituted nipecotyl derivatives as inhibitors of cell adhesion
AU2001271027B2 (en) * 2000-07-11 2005-07-07 Msd K.K. Ester derivatives
JP4445704B2 (ja) 2000-12-22 2010-04-07 アルミラル・ソシエダッド・アノニマ キヌクリジンカルバメート誘導体およびm3アンダゴニストとしてのそれらの使用
IL156558A0 (en) 2000-12-28 2004-01-04 Almirall Prodesfarma Ag Novel quinuclidine derivatives and medicinal compositions containing the same
DE10111843A1 (de) * 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Verbindungen zur Behandlung von inflammatorischen Erkrankungen
WO2003026564A2 (en) * 2001-09-27 2003-04-03 Pharmacia Ab Pharmaceutical compositions for the treatment of urinary disorders
ES2203327B1 (es) * 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
AU2002345266B2 (en) 2002-07-08 2009-07-02 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
HK1079787A1 (zh) 2002-07-31 2006-04-13 Ranbaxy Laboratories Limited 用作毒蕈碱受体拮抗剂的3,6-二取代的氮杂双环[3.1.0]己烷衍生物
HK1079708A1 (zh) 2002-08-09 2006-04-13 Ranbaxy Laboratories, Ltd. 可用作毒蕈碱性受体拮抗剂的3,6-二取代氮杂二环[3.1.10]己烷衍生物
US6583103B1 (en) 2002-08-09 2003-06-24 S.C. Johnson & Son, Inc. Two part cleaning formula resulting in an effervescent liquid
JP2006501236A (ja) 2002-08-23 2006-01-12 ランバクシー ラボラトリーズ リミテッド ムスカリン性レセプター拮抗薬としてのフルオロおよびスルホニルアミノ含有3,6−二置換アザビシクロ(3.1.0)ヘキサン誘導体
BR0315747A (pt) * 2002-10-29 2005-09-06 Pharmacia & Upjohn Co Llc Compostos de amÈnio quaternário como antagonistas de receptor muscarìnico
TW200800953A (en) 2002-10-30 2008-01-01 Theravance Inc Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine
US7232835B2 (en) 2002-12-10 2007-06-19 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists
WO2004054560A1 (en) 2002-12-13 2004-07-01 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
EP1581522B1 (en) 2002-12-23 2008-02-20 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
AU2002347552A1 (en) * 2002-12-23 2004-07-14 Ranbaxy Laboratories Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
US7488748B2 (en) 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
WO2004089898A1 (en) 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
AU2003223010A1 (en) * 2003-04-10 2004-11-01 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
DE60313898T2 (de) 2003-04-10 2008-01-17 Ranbaxy Laboratories, Ltd. Substituierte azabicyclo hexane derivate als muscarin rezeptor antagonisten
EA009387B1 (ru) * 2003-04-11 2007-12-28 Рэнбакси Лабораториз Лимитед Азабициклические производные в качестве антагонистов мускаринового рецептора
WO2004091597A2 (en) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Method of treating irritable bowel syndrome (ibs)
WO2005007645A1 (en) 2003-07-11 2005-01-27 Theravance, Inc. Substituted 4-amino-1-benzylpiperidine compounds
US7345060B2 (en) 2003-11-21 2008-03-18 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
CA2553160C (en) * 2003-12-29 2010-09-28 Banyu Pharmaceutical Co., Ltd. 2-heteroaryl-substituted benzimidazole derivative
EP1765809B1 (en) * 2004-06-16 2008-12-31 Ranbaxy Laboratories Limited Xanthine derivatives useful as muscarinic receptor antagonists
EP1781607A2 (en) * 2004-08-19 2007-05-09 Ranbaxy Laboratories Limited Pyrrolidine derivatives as muscarinic receptor antagonists
EP1794161A2 (en) * 2004-09-24 2007-06-13 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
EP1797040A1 (en) * 2004-09-29 2007-06-20 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
CA2586056C (en) 2004-11-02 2012-03-13 Banyu Pharmaceutical Co., Ltd. Aryloxy-substituted benzimidazole derivative
WO2006054162A1 (en) * 2004-11-19 2006-05-26 Ranbaxy Laboratories Limited Azabicyclic muscarinic receptor antagonists
WO2006064304A1 (en) * 2004-12-15 2006-06-22 Ranbaxy Laboratories Limited Acid addition salts of muscarinic receptor antagonists
EP1888525A1 (en) * 2005-05-03 2008-02-20 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives as muscarinic receptor antagonists
AU2006295645B2 (en) * 2005-09-30 2011-09-29 Msd K.K. 2-heteroaryl-substituted indole derivative
WO2007039884A1 (en) * 2005-10-05 2007-04-12 Ranbaxy Laboratories Limited 3 -azabicyclooctane derivatives as muscarinic receptor antagonists
RU2008119323A (ru) 2005-10-19 2009-11-27 Рэнбакси Лабораториз Лимитед (In) Фармацевтические композиции мускаринового рецептора
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
JP2008081492A (ja) 2006-08-31 2008-04-10 Banyu Pharmaceut Co Ltd オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
US20090010923A1 (en) * 2007-04-24 2009-01-08 University Of Maryland, Baltimore Treatment of cancer with anti-muscarinic receptor agents
KR101517574B1 (ko) * 2007-09-07 2015-05-07 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 무스카린 수용체 길항제로서 유용한 구아니딘을 함유하는 화합물
KR101247418B1 (ko) * 2007-12-21 2013-03-25 에프. 호프만-라 로슈 아게 항체 제형
CN104876854B (zh) * 2015-04-16 2017-03-01 御盛隆堂药业有限责任公司 羟基乙酸酯衍生物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6018661B2 (ja) * 1976-01-01 1985-05-11 太田製薬株式会社 1−(1,3−ジオキソラン−4−イルメチル)ピペリジノ−ル誘導体
JPS5679688A (en) * 1979-12-04 1981-06-30 Ota Seiyaku Kk 4-acyloxy-1- 1,3-dioxoran-2-ylmethyl piperidine derivative and its production
IT1231238B (it) * 1987-09-21 1991-11-26 Angeli Inst Spa Derivati ammidinici
GB8825505D0 (en) * 1988-11-01 1988-12-07 Pfizer Ltd Therapeutic agents
GB9023023D0 (en) * 1990-10-23 1990-12-05 Barlow Richard B Pharmaceutical compositions
CA2123728A1 (en) * 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
WO1995006635A1 (en) * 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
JP3294961B2 (ja) * 1993-12-10 2002-06-24 杏林製薬株式会社 新規イミダゾール誘導体及びその製造法
JPH07258250A (ja) * 1994-03-25 1995-10-09 Yamanouchi Pharmaceut Co Ltd エステル誘導体
EP0823423B1 (en) * 1995-04-28 2004-06-16 Banyu Pharmaceutical Co., Ltd. 1,4-disubstituted piperidine derivatives
CA2179574A1 (en) * 1995-06-26 1996-12-27 Tomomi Okada Substituted piperidine derivative and medicine comprising the same
ATE205490T1 (de) * 1995-10-13 2001-09-15 Banyu Pharma Co Ltd Substituierte heteroaromatische derivate

Also Published As

Publication number Publication date
TR199900204T2 (xx) 2000-01-21
ES2188961T3 (es) 2003-07-01
CO4960641A1 (es) 2000-09-25
EE9900038A (et) 1999-08-16
US5948792A (en) 1999-09-07
CZ33199A3 (cs) 1999-07-14
TR200001482T2 (tr) 2000-11-21
ATE229941T1 (de) 2003-01-15
ID17259A (id) 1997-12-11
WO1998005641A1 (en) 1998-02-12
US6040449A (en) 2000-03-21
NO990472D0 (no) 1999-02-01
HUP9902381A3 (en) 2000-06-28
JP3063164B2 (ja) 2000-07-12
CA2261680A1 (en) 1998-02-12
AR008272A1 (es) 1999-12-29
AR016877A2 (es) 2001-08-01
YU1299A (sh) 2002-03-18
EP0930298B1 (en) 2002-12-18
KR20000022214A (ko) 2000-04-25
AR017021A1 (es) 2001-08-22
DE69718026D1 (de) 2003-01-30
AU3635197A (en) 1998-02-25
PL331431A1 (en) 1999-07-19
NZ333842A (en) 2001-05-25
HRP970426A2 (en) 1998-08-31
CN1226888A (zh) 1999-08-25
SK12299A3 (en) 2000-05-16
NO990472L (no) 1999-02-01
AU716050B2 (en) 2000-02-17
IS4960A (is) 1999-01-29
PE92198A1 (es) 1999-01-09
DE69718026T2 (de) 2003-07-10
IL127685A0 (en) 1999-10-28
BR9711108A (pt) 1999-08-17
EP0930298A4 (en) 2000-06-07
CA2261680C (en) 2005-03-08
EP0930298A1 (en) 1999-07-21
HUP9902381A2 (hu) 1999-11-29

Similar Documents

Publication Publication Date Title
BG103114A (bg) Съдържащи флуор 1,4-дизаместени производни на пиперидин
DE69720773T2 (de) SAUERSTOFF ODER SCHWEFEL ENTHALTENDE 5-GLIEDRIGE HETEROAROMATISHE DERIVATIVE ALS FACTOR Xa HEMMER
TR200100659T2 (tr) 5-HT2C agonistleri olarak piroloindoller, piridoindoller ve azepinoindoller.
DE69418704D1 (de) Anthranilsäure derivate
ATE173256T1 (de) Azolidindion-derivate und ihre anwendung als antihyperglykämika
TW430660B (en) Novel benzindole derivatives for neuron cell protection, processes for production, and the pharmaceutical compounds containing them
NO306237B1 (no) Anvendelse av xantinderivater som antidepressive midler
UA48937C2 (uk) Імідазолідини, заміщені гетероциклом, спосіб їх одержання і фармацевтична композиція, що їх містить
ATE283268T1 (de) 2-adamantylethylamine und deren verwendung bei der behandlung von abnormalitäten in der glutamat transmission
ES2126075T3 (es) Derivados biciclicos nitrogenados como inhibidores de la propil-endopeptidasa.
DK0572635T3 (da) Hidtil ukendte forbindelser med guanidinstruktur og farmaceutisk komposition indeholdende forbindelserne
ES2184318T3 (es) 6-alquilfenantridinas sustituidas.
ATE224358T1 (de) Diaminocyclobuten-3,4-dionderivate, deren herstellung und deren verwendung
ATE225767T1 (de) 3,4-disubstituierte phenylethanolaminotetralin- carboxamid-derivate
DE69713067D1 (de) Aminotetralinderivate, deren zusammensetzungen sowie deren verwendung
TW333532B (en) Benzopyrans
DE69402935D1 (de) Substituierte arylalkylaminobenzyl-aminopropanamide, ihre herstellung und verwendung als antiepileptische, neuroprotektive und antidepressive mittel
ES2182509T3 (es) Derivados de n-ariloxietilamina para el tratamiento de la depresion.
DE69824476D1 (de) Alkylene-Derivat, Anti-ulcus und antibakterielle Arzneimittel
AR021094A1 (es) Compuestos heterociclicos inhibidores de la fosfodiesterasa iv y su uso para el tratamiento de enfermedades inflamatorias
MX9709465A (es) Derivados de bencimidazol 2-sustituidos como inhibidores de la proliferacion de celulas del musculo liso.
DE69706355D1 (de) Alkylendiamin-Derivate als Arzneimittel zur Behandlung von Geschwüren und Hemmung von Helicobacter pylori
CA2213197A1 (en) Certain bridged 4-phenyl-2-aminomethylimidazoles; new dopamine receptor subtype specific ligands
DK0784973T3 (da) Quinoxalinderivater til behandling af tinnitus
DE69706012D1 (de) N-Acylpiperazinderivat, antibakterielle und gegen Geschwüre wirksame Medikamente